ESMO 2017: New Data Confirms Superiority of Docetaxel-Based Triplet Therapy in Esophagogastric Cancer
The superiority of docetaxel-based triplet therapy over standard of care in patients with resectable esophagogastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA27_PR).
Survival in resectable esophagogastric cancer is poor. Five-year overall survival is around 25% with surgery, and is increased to 36% by adding a perioperative regimen of epirubicin, cisplatin, and infused fluorouracil (ECF). Phase II studies have shown encouraging pathologic response rates with perioperative docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT).
FLOT4 Trial
The phase III FLOT4 trial randomized 716 patients with resectable gastric or gastroesophageal junction adenocarcinoma to perioperative FLOT or ECF. As previously reported, FLOT was superior to ECF for all efficacy endpoints, including curative resection rates, progression-free survival, and overall survival.
At ESMO, researchers reported the results of multivariate, subgroup, and sensitivity analyses for the first time.
The relative effect of FLOT was observed in all subgroups, including the elderly and signet cell tumors, and was particularly pronounced in Siewert type 1 esophageal tumors (hazard ratio [HR] = 0.60), Barrett tumors (HR = 0.62), small tumors (HR = 0.66), and node-negative tumors (HR = 0.64).
Lead author Salah-Eddin Al-Batran, MD, Director, Institute of Clinical Cancer Research, UCT-University Cancer Centre, Krankenhaus Nordwest, Frankfurt, Germany, said: “These new analyses confirm the superiority of FLOT, which is the new standard of care in the perioperative treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma.”
He concluded,“Some oncologists believe that patients with small tumors and those with signet cell cancer should not be treated preoperatively. The results of the FLOT4 trial contradict this and show that these patients do benefit.”
Commentary
Commenting for ESMO, Michel Ducreux, MD, PhD, Head, Gastrointestinal Oncology Unit, Gustave Roussy, Villejuif, France, said: “The triplet regimen used in the FLOT4 trial was developed to improve the results of ECF. It decreased toxicity by replacing epirubicin with low-dose docetaxel and using oxaliplatin instead of cisplatin. FLOT is also more convenient to use, with one 24-hour infusion every 2 weeks rather than continuous infusion of fluorouracil in the ECF protocol.”
“The results show that FLOT is clearly the new standard of care,” continued Dr. Ducreux. “The new analysis presented at the ESMO 2017 Congress shows that the advantage of the FLOT regimen was seen across all subgroups, including those with a very poor prognosis, such as the elderly and patients with signet cell tumors.”
He concluded, “FLOT will be the best backbone of chemotherapy that we can use in this setting. A step forward would be to try to improve the results by adding targeted therapies or immune checkpoint inhibitors. It would also be interesting to know if the FLOT regimen shows different levels of effectiveness in the four molecular biologic subgroups of gastric cancer.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
